Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Immunotherapy Propels Urothelial Carcinoma Treatment Advances

February 2nd 2023

Stephanie A. Berg, DO, highlights ongoing urothelial cancer clinical trials; the role of single-agent immunotherapy and combinations in this disease; and the importance of future research that prioritizes and guides individualized patient care.

IK-175 Monotherapy or Plus Nivolumab Shows Early Activity in Urothelial Cancer

January 22nd 2023

IK-175 was found to be well tolerated in patients with advanced solid tumors and to elicit responses in those with urothelial cancer when used alone or in combination with nivolumab, according to initial data from an ongoing phase 1a/b study.

Dr. Zhang on the EV-302 Trial in Metastatic Urothelial Cancer

January 16th 2023

Tian Zhang, MD, discusses the investigation of the combination of enfortumab vedotin plus pembrolizumab in the phase 3 EV-302 trial in the frontline setting for metastatic urothelial cancer.

Dr. Aragon-Ching on the Use of Maintenance Avelumab in Urothelial Carcinoma

January 6th 2023

Jeanny B. Aragon-Ching, MD, FACP, discusses the use of maintenance avelumab as the standard-of-care treatment for patients with locally advanced or metastatic urothelial carcinoma.

FDA Grants Fast Track Status to BT8009 for Previously Treated Locally Advanced or Metastatic Urothelial Cancer

January 5th 2023

The FDA has granted a fast track designation to BT8009 for use as a monotherapy in adult patients with previously treated locally advanced or metastatic urothelial cancer.

Trilaciclib Plus Chemotherapy and Avelumab Maintenance Generates Comparable ORR in Advanced/Metastatic Urothelial Carcinoma

January 5th 2023

Adding the CDK4/6 inhibitor trilaciclib to platinum-based chemotherapy and avelumab maintenance produced an overall response rate comparable to chemotherapy and maintenance avelumab alone in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

N-803 Plus BCG Generates Strong, Durable Response in Non–Muscle Invasive Bladder Cancer

January 4th 2023

N-803, a novel IL-15 superagonist, in combination with intravesical Bacillus Calmette–Guérin induced an overall response in more than two-thirds of patients with non–muscle invasive bladder cancer.

FDA Accepts sBLAs for Enfortumab Vedotin/Pembrolizumab in Advanced Urothelial Cancer

December 20th 2022

The FDA has granted a priority review to a supplemental biologics license applications for enfortumab vedotin and pembrolizumab used in combination for the treatment of patients with locally advanced or metastatic urothelial cancer who are not eligible to receive cisplatin-containing chemotherapy.

FDA Approves Nadofaragene Firadenovec for High-risk Non–Muscle Invasive Bladder Cancer

December 16th 2022

The FDA has approved nadofaragene firadenovec-vncg (Adstiladrin) for the treatment of adult patients with high-risk Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.

Budigalimab Plus ABBV-151 Demonstrates Variable Activity Across Locally Advanced or Metastatic Solid Tumors

December 6th 2022

The addition of budigalimab to ABBV-151 was well tolerated and significantly enhanced responses in patients with locally advanced or metastatic solid tumors.

Dr. Schmid on Next Steps for the RACE IT Trial in Urothelial Carcinoma

December 1st 2022

Sebastian C. Schmid, MD, discusses the future of the phase 2 RACE IT trial in urothelial carcinoma.

CG0070/Pembrolizumab Combo Shows Promising Efficacy and Tolerability in NMIBC

November 30th 2022

The oncolytic vaccine CG0070 plus pembrolizumab demonstrated encouraging response rates and a tolerable safety profile in patients with non–muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guérin.

Roche to Withdraw US Indication for Atezolizumab in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

November 29th 2022

Roche is voluntarily withdrawing the United States indication for atezolizumab for the treatment of adults with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.

Dr. Schmid on the Rationale for the RACE IT Trial in Advanced Urothelial Carcinoma

November 15th 2022

Sebastian C. Schmid, MD, discusses the rationale for the phase 2 RACE IT trial in urothelial carcinoma.

Dr. Gupta on the Investigation of Enfortumab Vedotin With or Without Additional Therapy in mUC

November 14th 2022

Shilpa Gupta, MD, discusses the investigation of enfortumab vedotin with or without additional therapy in cisplatin-ineligible metastatic urothelial carcinoma.

Dr. Siefker-Radtke on Unmet Needs in Frontline Urothelial Cancer Treatment

November 14th 2022

Arlene O. Siefker-Radtke, MD, discusses key therapeutic developments aimed at addressing unmet needs in metastatic urothelial carcinoma treatment.

Dr. Siefker-Radtke on Erdafitinib in Urothelial Carcinoma

November 11th 2022

Arlene O. Siefker-Radtke, MD, discusses the use of erdafitinib in urothelial carcinoma.

Petrylak Previews Shift in Sequencing Paradigm in Urothelial Cancer

November 9th 2022

Daniel P. Petrylak, MD, highlights the use of checkpoint inhibitors, antibody-drug conjugates, and FGFR inhibitors in urothelial cancer and the current sequencing hurdles in the paradigm.

Dr. Gupta on Unmet Needs in Frontline Treatment of Metastatic Urothelial Cancer.

November 4th 2022

Shilpa Gupta, MD, discusses the unmet needs of patients with cisplatin-ineligible metastatic urothelial carcinoma.

Dr. Sonpavde on the Investigation of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

October 31st 2022

Guru P. Sonpavde, MD, discusses the investigation of enfortumab vedotin-ejfv with or without pembrolizumab in urothelial cancer.